Chinese Pharma Market will Reach $158bn in 2016, Shows New Visiongain Report

LONDON, May 7, 2013 /PRNewswire/ --

A new report by visiongain predicts the overall pharma market in China will reach $158bn in 2016. The market generated $88bn in 2012 and its revenues will show strong growth to 2023. That forecast and others appear in Chinese Pharmaceutical Market 2013-2023, published in April 2013. Visiongain is a business information provider based in London, UK.

That study predicts double-figure expansion in all sectors of the Chinese pharmaceutical market, with rural sales outlets particularly benefitting from the government's investment in healthcare. Biologics (biological drugs) will increase their market share, driven by biosimilar uptake, while sales of novel biologics will be stimulated by innovations such as Roche's private insurance scheme for Herceptin. China's under-met needs in chronic disease areas will continue to stimulate healthcare spending, with cancer treatments replacing anti-infective agents as the largest market segment before 2020.

Recent governmental reforms have not been uniformly beneficial for the pharma industry, the report indicates. Implementation of the 'Anhui model' has spread, and has reportedly forced down drug prices by up to 35%. Questions also remain over technology transfer in the pharmaceutical sector as China moves towards becoming an innovator. Also, future tensions are likely between China's national development imperatives and the needs of healthcare industries covered in the study.

Dr James Evans, a pharmaceutical industry analyst in visiongain, said: "While China presents challenges in terms of the government's role, the size of the country and its variable levels of infrastructure, difficulties over IP, transparency, regulation, and so on, the worldwide pharma industry feels impelled to enter and expand in the Chinese healthcare market.

"China's disease burden is vast and growing, and in every area there are unmet medical needs that international pharmaceutical companies can address. The big multinationals have already committed to China by building up their sales forces there - there are now more boots on the ground in China than there are even in the US. Furthermore, the pharma industry continues to relocate manufacturing and research operations to China, cutting costs and also helping to get a foothold and win influence there. Projects like AstraZeneca's Innovation Center China and Sanofi's China Initiative for Diabetes Excellence are about differentiating therapies for the Chinese market, creating China-specific approaches. That's worth doing when it's China you're doing it for - a country with a vast, idiosyncratic market with great commercial potential remaining.

"We also see companies like GSK and Novartis looking at traditional Chinese medicines (TCM), which may be an if you can't beat 'em, join 'em decision. Anyhow, China's output of TCM is growing rapidly, especially as the government has kept TCM at the centre of its Twelfth Five-Year Plan. Therefore, TCM isn't receding. It looks like Big Pharma is now acknowledging it has to be in that segment too, to have a portfolio that will work in China."

Visiongain's study concludes that the Chinese market will remain at the centre of the worldwide pharma industry's growth strategies to 2023, with companies continually adapting to China's challenges and opportunities.

That new investigation shows revenue forecasts to 2023 at overall national market and submarket level. The analyses cover small-molecule drugs (including generics), TCM, biologics (including biosimilars), medical devices and outsourced pharma activities.

Chinese pharmaceutical Market 2013-2023 thus adds to visiongain's range of analytical reports on emerging industries and markets in healthcare.

 For sample pages and further information concerning the visiongain report Chinese Pharmaceutical Market 2013-2023  please visit

http://www.visiongain.com/Report/1018/Chinese-Pharmaceutical-Market-2013-2023

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com

Tel:+44(0)2073366100

Companies Listed

3SBio
Abbvie (Abbott Laboratories)
Acambis
Advanced Biologics
Advexin
Agilent
Alliance Boots
Amgen
Anhui BBCA Biochemical
AppTech Laboratory Services
Asian Cancer Research Group
Astellas
AstraZeneca
Aurobindo
AutekBiom
Baxter
Bayer Healthcare
BeiGene
Beijing Bionovo Medicine Development
Beijing Four Rings
Beijing Kexing Bioproducts
Beijing Northland Biotech
Beijing Sihuan
Beijing SL Pharmaceutical
Beijing Taiyang
Beijing Tongrengtang Pharmaceutical
Beijing University
Beijung Tiantan Biological Products
BGI (formerly Beijing Genomics Institute)
Bio-Bridge Science
BiODura
BioDuraBio-pharmaceutical
Biotech Pharmaceutical
BMP Sunstone
Boehringer Ingelheim
Bristol-Myers Squibb
Broad Institute
Buchang Pharmaceutical
Cancer Foundation of China
Cancer Therapeutics
CASiGEN Pharma
Celgene
Charles River Laboratories
Chemizon (Beijing) Pharma-Tech
Chengdu Di'ao Pharmaceutical Group
Chengdu Institute of Biological Products
Chengdu Kanghong Biotech
China Aoxing
China National Accord Medicines
China National Biotec Group
China National Center for Drug Screening
China National Medicines
China Nepstar Chain Drugstore
China OTC Association
China Otsuka Pharmaceutical
China Pharmaceutical Commerce Association
China Pharmaceutical Quality Management Association
China Resources Double Crane Pharmaceutical
China Sky One Medical
ChinaGate
Chinese Academy of Medical Sciences
Chinese Academy of Sciences
Chinese Centre for Disease Control and Prevention
Chinese Diabetes Society
Chongqing Fortune Pharmaceutical
Chongqing Taiji Industry
Cipla
Cord Blood America
Covance
Crown Bioscience
Cumencor
Daiichi Sankyo
Denosim
Diapin Therapeutics
Dr. Reddy's Laboratories
Egret
Eisai
Eli Lilly
Epitomics
Excel PharmaStudies
FeRx
Frontage Laboratories
Fudan University
Fuzhou Fuxing Pharmaceutical
Gan & Lee Pharmaceutical
Gendicine
GeneScience Pharmaceuticals
Genor Biomanufacturing
Genzyme
Gilead Sciences
GlaxoSmithKline
Golden Meditech Holdings
Greater China Corporation
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Guangdong BeiKang Pharmaceutical
Guangdong Province People's Hospital
Guangzhou Institute of Biomedicine and Health
Guangzhou Medical University
Guangzhou Pharmaceutical
Guizhou Baiqiang Pharmaceutical
Hainan Litzman Pharmaceutical
Hangzhou Huadong Medicine Group
Hangzhou Jiuyuan Gene Engineering
Hangzhou Sanofi-Synthelabo Minsheng
Hangzhou Tigermed Consulting
Hangzhou Zhongmei Huadong Pharmaceutical
Harbin Pharmaceutical
HD Biosciences
Hebei Medical University
Hengrui
HitGen
Huadong Medicine
Hualan Biological Engineering
Hualida Biotech
Huazhong University of Science and Technology
Hutchison MediPharma
i3 Research
ICON
Inner Mongolia Yili Energy
Institute for BioMedical Research (Shanghai)
International Diabetes Foundation
Introgen
Isotechnika Pharma
Ivax
Jiangsu Hansen Pharmaceutical
Jiangsu Hengrui Medicine
Jiangsu New Medicine Research Institution
Jiangsu Province Hospital
Jiangsu Walvax Biotech
Johnson & Johnson
Joincare Pharma
Jointown Pharmaceutical
Kanda Biotechnology
Kangmei Pharmaceutical
Lee's Pharmaceutical
Lepu Medical
Livzon Pharmaceutical Group
Lundbeck
Matrix Laboratories
Medigen Biotechnology Corporation
Medtronic
Merck & Co.
Merck Serono
Merck Sharp & Dohme
Microport Medical
MicuRx Pharmaceuticals
Mindray
Ministry of Commerce
Ministry of Health
Ministry of Labor and Social Security
Ministry of Science and Technology
Minsheng Pharmaceutical
Mirahi Biotech
Mylan
Nanfang Hospital of Southern Medical University
Nanjing Hailing National Engineering Research Center for TCM Manufacturing Technology
Nanjing Kanghai Pharmaceutical
Nanjing Pharmaceutical
Natco Pharma
National Development and Reform Commission
Nestle
Netherlands Organization for Applied Scientific Research
NeuroVive
Newsummit Biopharma
North China Pharmaceutical Group
Northeast General Pharmaceutical
Northeast Pharmaceutical Group (NEPG)
NovaMed Pharmaceuticals
Novartis
Novast Labs
Novo Nordisk
Otsuka
Otsuka Beijing Research Institute
Ouyi Pharma
Pacific MeinuoKe
Panion & BF Biotech
Patheon
Peking University People's Hospital
Pfizer
Pharmaron
PPD
PRA
Pro Top & Mediking
Psyma Business Research China
Qilu Antibiotics
Qilu Pharmaceutical
QRxPharma
Quintiles
Regenex Corporation
Roche
S&P Pharmaceutical Industry
Sanofi
Schering-Plough
Shandong Dong-E E-Jiao
Shandong Kexing Bioproducts
Shandong Lanjin Pharmaceuticals
Shandong Luye Pharmaceutical
Shangdong Weigao Group
Shanghai BravoBio
Shanghai Celgen Bio-Pharmaceutical
Shanghai Charity Foundation
Shanghai ChemExplorer
Shanghai Clinical Research Centre
Shanghai Fosun Pharma
Shanghai Greenvalley Pharmaceutical
Shanghai Hotmed Sciences
Shanghai Institutes of Biological Sciences
Shanghai Jiao Tong University School of Medicine
Shanghai Jinhe Bio-Technology
Shanghai MengKe Pharmaceuticals
Shanghai Mental Health Center
Shanghai Pharma
Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales
Shanghai Zhangjiang Biomedical Industry Venture Capital
ShangPharma
Shantou Institute of Ultrasonic Instruments
Shenyang Sunshine
Shenzhen Kangzhe Pharmaceutical
Shenzhen Neptunus Bioengineering
Shenzhen SiBiono GeneTech
Shenzhen Wenle ('Main Luck') Pharmaceutical
Shijiazhuang Pharmaceutical Group
Shire
Sichuan Jiufeng Pharmaceutical
Sichuan Kelun Pharmaceutical
Sicor
Sihuan Pharmaceutical Holdings
Simcere Pharmaceutical
Simcere-MSD (Simcere Pharmaceutical - Merck jv)
SiniWest Holdings
Sino-American Kunming Baker Norton Pharmaceutical
Sinopharm
Sinovac Biotech
State Food and Drug Administration (SFDA)
State Key Lab of Respiratory Disease
State Population and Family Planning Commission
State Quality Control Administration
State Traditional Chinese Medicine Administration
Sumitomo Pharmaceutical (Suzhou)
Sundia Meditech
Sundiro Pharma
Sunway Biotech
Swiss Re
Symbio Pharmaceuticals
TaiGen Biotechnology
Takeda
Tangshan Yian Bioengineering
Tasly Pharmaceuticals
Teleos Healthcare
Teva Pharmaceutical Industries
The United Laboratories
Thermo Fisher Scientific
Third Affiliated Hospital, Sun Yat-Sen University
Thomas, McNerney & Partners
Tianjin International Joint Academy of Biotechnology and Medicine
Tianjin Jin Yao Group
Tianjin Medical University Cancer Hospital
Tianjin Nankai Hospital
Tianjin Pharmaceuticals Group Corporation (TJPC)
Tianjin Takeda Pharmaceuticals
Time Medical Systems
Tonghua Dongbao
Tongji University
Tongrengtang Pharmaceutical
Tsingua University
UNICEF
United Pharmatech
University of Michigan
Ventac Partners
Venturepharm Laboratories
Vertex Pharmaceuticals
Vinise Pharmaceutical
Vinise Pharmaceutical
Viva Biotech
Wanbang Biopharmaceuticals
World Customs Organisation
World Heath Organization (WHO)
World Trade Organisation
Wuhan National Bioindustry Base Construction
WuXi AppTec
Wuxi Pharma
Xiamen Amoytop Biotech
Xian-Janssen Pharmaceuticals
Yangtze River Pharmaceutical Group
Youcare Pharmaceutical Group
Yunnan Baiyao
Zensun (Shanghai) Sci & Tech
Zhejiang Beta Pharma
Zhejiang Hisun Pharmaceutical
Zhejiang Medicine
Zhejiang Tianyuan
Zhongnuo Pharmaceutical
Zhuhai United States Labs

Notes for Editors

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Automotive and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)207-336-6100